SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER

SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗

基本信息

批准号：
8351886
负责人：
PETER PUSHKO
金额：
$ 148.31万
依托单位：
MEDIGEN, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-29 至 2013-09-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8351886
关键词：
Animal Model Antibody Formation Antigens Biological Assay CD8B1 gene Cancer Control Chemistry Collaborations Contracts Data Dendritic Cells Development Dose Engineering Evaluation Genes Goals Human Immunotherapy Malignant neoplasm of prostate Maryland Methods Mus Phase Preparation Procedures Process Production Prostate Cancer Vaccine Prostate-Specific Antigen Public Health Quality Control Regimen Research Route Safety Serum Small Business Innovation Research Grant Structure of base of prostate Synthetic Vaccines T-Lymphocyte Transgenic Mice United States Food and Drug Administration Universities Vaccinated Vaccination Vaccine Antigen Vaccine Production Vaccines Variant Virus-like particle assay development cancer immunotherapy design expression vector follow-up immunogenicity improved in vivo meetings novel novel therapeutics novel vaccines protective effect protective efficacy research study scale up therapeutic vaccine tumor vaccine candidate vaccine efficacy vector

项目摘要

This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novel ¿vector VLP¿ (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.

该II期SBIR合同用于晚期疫苗效率研究，涉及接种疫苗的PSA+转基因小鼠的流浪汉肿瘤挑战。使用新颖的Vlp_疫苗疫苗平台（VVLP_疫苗平台。后者表示非复制病毒样颗粒），将在PSA+小鼠中传递并表达用于提高免疫原性PSA变体的工程设计。